Radiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York
|
|
- Jane Barton
- 5 years ago
- Views:
Transcription
1 Radiotherapy in DLCL is often worthwhile Dr. Joachim Yahalom Memorial Sloan-Kettering, New York
2 The case for radiotherapy Past: Pre-Rituximab randomized trials Present: R-CHOP as backbone, retrospective data Upcoming data: Finally, a randomized trial with RT question (UNFOLDER) Data on value of RT to bulky sites PET as treatment- or RT dose- modifier Shrinking the involved RT field (involved-node or involved site)- New ILROG Guidelines Adaptive RT dose
3 Chemo alone vs. CMT pre-rituximab trials Trial Pt. Characteristics No. Treatment Arms Results p-value SWOG, 1998 Median age: 59 Normal LDH: 80% PS 0-1: 97% % stage II: 33% Excl. bulky stage II 401 CHOPx3+RT CHOPx8 5-yr PFS: 77% 5-yr OS: 92% 5-yr PFS: 64% 5-yr OS: 72% p=0.03 p=0.02 ECOG, 2004 Median age: 59 PS 0-1: 92% % stage II: 68% % bulky: 31% 399 CHOPx8: RT If CR (n=215) no RT If PR (n=71) RT 6-yr FFS: 70% 6-yr OS: 79% 6-yr FFS: 53% 6-yr OS: 67% 6-yr FFS: 63% 6yr OS: 69% p=0.05 p=0.23 LNH Median age: 47 Normal LDH, PS 0-1 % stage II: 32% % bulky: 11% 647 CHOPx3+RT ACVBP 5-yr EFS: 74% 5-yr OS: 81% 5-yr EFS: 82% 5-yr OS: 90% p<0.001 p=0.001 LNH Median Age: 68 Normal LDH, PS 0-1 % stage II: 32% % bulky: 9% 574 CHOPx4+RT CHOPx4 5 yr EFS: 64% 5-yr OS: 68% 5-yr EFS: 61% 5-yr OS: 72% p=0.56 p=0.54
4 SWOG 8736 randomized trial Stage II 32% Bulky 3%
5 SWOG 8736 trial Chemotherapy alone compared with chemotherapy plus RT for localised intermediate and high grade lymphoma Miller et al 1998 NEJM 339 (1) PFS and OS curves of began to overlap at 7 years and at 9 years after treatment, respectively
6 Miller TP, et al., ASH, STILL UNPUBLISHED
7 Pt. Characteristics No. Treatment Arms Results p-value Median age: 59 Normal LDH: 80% PS 0-1: 97% % stage II: 33% Excl. bulky stage II 401 CHOPx3+RT CHOPx8 5-yr PFS: 77% 5-yr OS: 92% 5-yr PFS: 64% 5-yr OS: 72% p=0.03 p= RT can substitute for 5 cycles of CHOP and provide significantly better outcome - Increased cardiac toxicity with prolonged chemo - Excellent outcome in pts with SA IPI of 0 treated with CHOPx3 +RT - Updated data at median f/u of 8.2 yrs: FFS and OS curves overlapped - Is CHOPX3 adequate for all? Miller. NEJM, 1998 Miller. ASH, 2001
8 ECOG 1484 randomized trial Stage II- 68% Bulky- 31% Ex nodal- 47%
9 ECOG 1484 Pt. Characteristics No. Treatment Arms Results p-value Median age: 59 % stage II: 68% % bulky: 31% 399 CHOPx8: If CR (n=215) RT no RT 6-yr FFS: 70% 6-yr OS: 79% 6-yr FFS: 53% 6-yr OS: 67% p=0.05 p=0.23 If PR (n=71) RT 6-yr FFS: 63% 6yr OS: 69% 50% of registered were not randomized - Not powered to detect < 20% increase in OS with RT - 20% of CR pts did not receive assigned treatment - More bulky pts in RT arm vs observation arm: 26% vs 17% - No information on type of mortality events when median age of survivors is over 70. Horning. JCO, 2004
10 % Time to Progression in CR Patients According to Consolidation % TTP Yr RT Obs p = 0.06 RT (79) Obs (93) Years
11 CHOP +/- RT for Limited Stage Aggressive NHL % OS in CR Patients Yr RT Obs p = 0.24 Update of ECOG Trial 1484 OS CR 30 Gy CR Obs PR 40 Gy Years
12 GELA LNH 93-1 randomized trial Stage II-32% Bulky-11%
13 GELA LHN 93-1 (age<60) Pt. Characteristics No. Treatment Arms Results p-value Median age: 47 Normal LDH, PS 0-1 % stage II: 32% % bulky: 11% 647 CHOPx3+RT ACVBP 5-yr EFS: 74% 5-yr OS: 81% 5-yr EFS: 82% 5-yr OS: 90% p<0.001 p= No difference in non-bulky (<10 cm) pts. - ACVBP: established survival advantage over 8 cycles of CHOP in advanced-stage pts - High rate of short and long-term toxicity of ACVBP - Difficult to justify ACVBP in low-risk pts Reyes. NEJM, 2005
14 GELA NHL 93-4 randomized trial Stage II- 32% Bulky - 8%
15 GELA LNH 93-4 (age>60) Pt. Characteristics No. Treatment Arms Results p-value Median Age: 68 Normal LDH, PS 0-1 % stage II: 32% % bulky: 8% 574 CHOPx4+RT CHOPx4 5 yr EFS: 64% 5-yr OS: 68% 5-yr EFS: 61% 5-yr OS: 72% p=0.56 p= Long delay between chemo to RT (median 7 weeks) - 12% pts did not receive RT as assigned, 23% underdosed. No quality assurance reported. - 23% failure in RT field (34% with local component) - More deaths from lymphoma progression in the RT arm (70 vs 65) difficult to explain - More deaths from SM in the RT arm (20 vs 9), though only 3 of 20 SM were in-field Bonnet. JCO, 2007
16 Large cohort studies failing to show increased SM risk with addition of RT: BNLI: Retrospective cohort study of 2,456 NHL pts SIR of solid cancer in no-rt cohort: 1.0 (95% CI, ) SIR of solid cancer in RT cohort: 1.2 (95% CI, ) SEER: Retrospective cohort study of 77,823 NHL pts : SIR of SM in no-rt cohort: 1.13 (95% CI, ) SIR of SM in RT cohort: 1.18 (95% CI, ) GISL: Retrospective cohort study of 1,280 DLBCL pts: SIR of SM in no-rt cohort: 1.16 (95% CI, ) SIR of SM in RT cohort: 0.92 (95% CI, ) Mudie et al. JCO 24:1568, 2006; Tward et al. Cancer 107:108, 2006; Sacchi et al. Haematologica 93: 298, 2008
17 Significant Dose-Related Cardiac Toxicity of Doxorubicin-Based Chemo: HR: 1.29, p< SEER-Medicare: - 9,438 patients age>65 with DLBCL (42% received doxo-based chemo) - Cox model after adjustment for age, gender, race, comorbidity, cardiac risk factors: HR for CHF no doxo chemo ref 1-3 cycles: cycles: 1.24 > 6 cycles: 1.47 Hershman. JCO 2008
18 Significantly Reduced Cardiac Mortality in Pts Treated with RT- May be Due to Use of Less Chemo: SEER Study: - 15,454 pts with stage I-II DLBCL diagnosed between from SEER database (39% received RT) - Significantly reduced risk of cardiac mortality with RT use (RR 0.74, 95% CI ) - MVA showed persistent protective effect of RT after controlling for age, gender, race stage, and extranodal disease Pugh. IJROBP 2010
19 Limited Disease ~ Aggressive Histology (SWOG 0014) Treatment Plan WEEKS R CHOP + R CHOP + R CHOP + R Involved-Field Radiotherapy (IFRT) R = Rituximab CHOP = cyclophosphamide, 750mg/m 2 doxorubicin, 50mg/m 2 vincristine, 2.0mg prednisone, 100mg x 5days IFRT = GY
20 SWOG Limited Stage 4xR + 3x CHOP + IFRT (40-46 Gy) Persky et al., J Clin Oncol 2008
21 Benefit of consolidative Radiation Therapy in Patients with DLBC treated with R-CHOP achieving CR (291 pts) Phan et al JCO 28 (27) % 73% 19 % 14 % Overall Survival Progression Free Survival 5 yr OS and PFS for stage I and II disease - R-CHOP + RT 92% and 82%, respectively; no RT, OS and PFS were 73% (P =.0007) and 68% (P =.0003), Improvements in PFS and OS also seen for minority with stage III and IV disease receiving RT. None of the patients experienced treatment failure in the RT field.
22 MD Anderson Experience 469 pts with DLBCL (30% received consolidative RT) Among 291 pts treated with R-CHOP and achieved CR, RT associated with significantly higher 5y OS and PFS MVA: RT associated with significantly improved PFS (HR, 0.19) and OS (HR, 0.32) Phan. JCO, 2010
23 Randomize patients in CR
24 Second Interim analysis by DSMC pts. July 2012 UNFOLDER Study (Germany) Age <60 aaipi=1 or aaipi=0 with bulky disease >7.5cm Randomize patients in CR
25 Reducing RT field in limited stage DLBCL Reducing the field from involved or regional field to involved site field was effective and safe. Pre-chemotherapy involved nodes No increase in in-field or marginal failures. Campbell B et al from Vancouver- Cancer 2012 INRT IFRT
26 IFRT Pre-chemotherapy involved nodes INRT 5cm
27 Patterns of failure Total (n = 288) IFRT (n = 138) INRT 5cm (n = 150) Total relapses 22% 23% 21% Infield relapse only 2% 2% 1% Distant relapse without infield relapse Distant only Marginal only Marginal + distant 17% 17% 17% % 13% 2% 2% Distant + infield relapse 3% 4% 3%
28 BNLI STUDY DESIGN PATIENT ELIGIBLE LOW GRADE LYMPHOMA INTERMEDIATE OR HIGH GRADE LYMPHOMA RANDOMISE RANDOMISE 24Gy 12 fractions 40-45Gy 45Gy fractions 30Gy 15 fractions 40-45Gy 45Gy fractions
29 30 Gy vs Gy Median f/u 5.6 yrs: 30 Gy Gy p-value (n=319) (n=321) CR 82% 83% - 5y FFLP 82% 84% y OS 64% 68% 0.29 Caveats: Included pts treated with RT alone or receiving salvage/palliative RT No chemo data, mostly without rituximab Lack of functional imaging to determine response to chemo Lowry et al Radiother Oncol 2011
30 When will RT exert the most benefit? Distribution of disease is restricted to site(s) that can be encompassed in a contiguous limited RT field RT can reduce the need for long intensive and more toxic chemotherapy Elderly patients (poor tolerance, limited salvage options) Bulky disease or extranodal disease Sub-optimal response to chemotherapy (PET positive or?) Special sanctuary sites (testis, CNS)
31
32 PET-Based Treatment Algorithm for Consolidative Radiation Therapy PET Neg Observe R-CHOP x 6-8 Residual 2cm PET Pos XRT If feasible Sehn et al., ASH 2010, Abstract # 854
33 Overall Survival According to PET Status and XRT (n=187) Percent Survival Pos PET-No XRT Pos PET-XRT Neg PET Time (years) Sehn et al., ASH 2010, Abstract #
34 SWOG Approach for Limited Stage 4xR + 3x CHOP + IFRT (40-46 Gy Persky et al., J Clin Oncol 2008
Radiotherapy in aggressive lymphomas. Umberto Ricardi
Radiotherapy in aggressive lymphomas Umberto Ricardi Is there (still) a role for Radiation Therapy in DLCL? NHL: A Heterogeneous Disease ALCL PMLBCL (2%) Burkitt s MCL (6%) Other DLBCL (31%) - 75% of aggressive
More informationThe treatment of DLBCL. Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona
The treatment of DLBCL Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona NHL frequency at the IOSI Mantle Cell Lymphoma 6.5 % Diffuse Large B-cell Lymphoma 37%
More informationHead and Neck: DLBCL
Head and Neck: DLBCL Nikhil G. Thaker Chelsea C. Pinnix Valerie K. Reed Bouthaina S. Dabaja Department of Radiation Oncology MD Anderson Cancer Center Case 60 yo male Presented with right cervical LAD
More informationDr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009
Treatment of DLBCL Dr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009 Non-hodgkin lymphomas DLBCL Most common NHL subtype throughout the world many other types of lymphoma with striking geographic variations
More informationNON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and
More informationTraitement des lymphomes diffus à grandes cellules B
Traitement des lymphomes diffus à grandes cellules B Corinne HAIOUN Unité Hémopathies Lymphoïdes- CHU Henri Mondor Université Paris Est Créteil DES Hématologie Février 2012 On February 10th, the merging
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationDr. Noelle O Rourke Beatson Oncology Centre, Glasgow RADIOTHERAPY FOR LYMPHOMA???
Dr. Noelle O Rourke Beatson Oncology Centre, Glasgow RADIOTHERAPY FOR LYMPHOMA??? History of Radiotherapy 1895 Rontgen describes X-rays 1896 Becquerel radioactivity 1905 Radiation is used to treat tumours
More informationASTRO Refresher Course Lymphoma. Chris Kelsey, M.D. Duke University Medical Center
ASTRO Refresher Course 2015 Lymphoma Chris Kelsey, M.D. Duke University Medical Center Disclosure Varian Medical Systems Research funding for lung cancer trial Learning Objectives Awareness of Deauville
More informationOriginal Article. Introduction
Original Article Radiat Oncol J 217;35(4):317-324 https://doi.org/1.3857/roj.217.451 pissn 2234-19 eissn 2234-3156 Treatment results of radiotherapy following CHOP or R-CHOP in limited-stage head-and-neck
More informationPET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationFirst Line Management of Classical Hodgkin Lymphoma
First Line Management of Classical Hodgkin Lymphoma George Follows Cambridge University Hospitals NHS Foundation Trust george.follows@addenbrookes.nhs.uk The controversial areas Early stage non-bulky /
More informationRADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA
RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin
More informationHave we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES!
Have we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES! Christopher Flowers, MD, MSc Associate Professor Director, Lymphoma Program Department of Hematology and Oncology Emory School of Medicine
More informationLYMPHOMA IN OLDER PEOPLE. Ama Rohatiner, St. Bartholomew s Hospital, Londonj
LYMPHOMA IN OLDER PEOPLE Ama Rohatiner, St. Bartholomew s Hospital, Londonj LYMPHOMA IN OLDER PEOPLE PERSPECTIVES HALF OF ALL NEWLY-DIAGNOSED PTS. WITH LYMPHOMA ARE >60 MAY REQUIRE DIFFERENT MANAGEMENT
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationLancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:
1 Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 2018-19 1.1 Pretreatment evaluation The following tests should be performed: FBC, U&Es, creat, LFTs, calcium, LDH, Igs/serum
More informationSupplementary Appendix to manuscript submitted by Trappe, R.U. et al:
Supplementary Appendix to manuscript submitted by Trappe, R.U. et al: Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful
More informationAddition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma
Original Article Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma Bo Jia 1, Yuankai Shi 1, Suyi Kang 1, Sheng
More informationFOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?
Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital
More information12 th Annual Hematology & Breast Cancer Update Update in Lymphoma
12 th Annual Hematology & Breast Cancer Update Update in Lymphoma Craig Okada, MD, PhD Assistant Professor, Hematology January 14, 2010 Governors Hotel, Portland Oregon Initial Treatment of Indolent Lymphoma
More informationHodgkin Lymphoma: Umberto Ricardi
Hodgkin Lymphoma: Radiation Volumes Umberto Ricardi Università di Torino The changing role of RT in the cure of HL From Maximal use as a single agent To Combination of chemotherapy and full dose-full volume
More informationRadiotherapy of Follicular Lymphoma: Updated Role and New Rules
Current Treatment Options in Oncology (2014) 15:262 268 DOI 10.1007/s11864-014-0286-4 Lymphoma (A Engert, Section Editor) Radiotherapy of Follicular Lymphoma: Updated Role and New Rules Joachim Yahalom,
More informationHow I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES
How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I Choose First Line Treatment in Follicular Lymphoma in 2017? 1. How do I take into account
More informationRole of PET in staging and treatment of lymphomas
Role of PET in staging and treatment of lymphomas ESMO preceptorship in lymphoma Madrid, 25 November 2016 Martin Hutchings Rigshospitalet, Copenhagen, Denmark EORTC Lymphoma Group PET in lymphoma staging
More informationRole of PET in staging and treatment of lymphomas
Role of PET in staging and treatment of lymphomas ESMO preceptorship in lymphoma Lugano, 3-4 November 2017 Martin Hutchings Rigshospitalet, Copenhagen, Denmark EORTC Lymphoma Group PET in lymphoma staging
More informationRituximab in the Treatment of NHL:
New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,
More informationCharacteristics and treatment of DLBCL in elderly patients
Characteristics and treatment of DLBCL in elderly patients Lysa Experience or From Stephan to Ruth Eli 5/02/16 F.Peyrade Nice France Age at Diagnosis http://seer.cancer.gov/ E(x) 10,00 9,00 8,00 7,00 6,00
More informationThe role of liposomal doxorubicin in DLBCL lymphomas. Michele Spina Aviano
The role of liposomal doxorubicin in DLBCL lymphomas Michele Spina Aviano Disclosures of Michele Spina Company name Research support Employee Consultant Stockholder Speakers bureau Advisory board Other
More informationLymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège. 14 th post-ash meeting, January 6 th 2011, Brussels
Lymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège 14 th post-ash meeting, January 6 th 2011, Brussels Hodgkin s lymphoma Follicular lymphoma Diffuse large B-cell lymphoma Mantle cell
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationOpen questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland
Open questions in the treatment of Follicular Lymphoma Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Survival of major lymphoma subtypes at IOSI 1.00 cause-specific
More informationUpdate on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Update on Limited Small Cell Lung Cancer Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Objectives - Limited Radiation Dose Radiation Timing Radiation Volume PCI Neurotoxicity
More informationChoice of upfront treatment in the management of diffuse large B-cell lymphoma and follicular lymphoma
Choice of upfront treatment in the management of diffuse large B-cell lymphoma and follicular lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationAddition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
VOLUME 46 ㆍ NUMBER 2 ㆍ June 2011 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
More informationDr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
More informationHodgkin Lymphoma Status of the art of treatment
11.05.2016 1 Hodgkin Lymphoma Status of the art of treatment Peter Borchmann German Hodgkin Study Group University of Cologne, Germany Question No 1: Which statement regarding 1 st line treatment of early
More informationLYSA PET adapted programs. O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France
LYSA PET adapted programs O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France 3 phase III trials DLBCL LNH 09-1B: aaipi = 0, 18 80y : ongoing GAINED: aaipi = 1-3, 18 60y : ongoing
More informationJournal of American Science 2016;12(6)
Role of reduced dose CHOP with Rituximab plus involved field radiotherapy in treatment of early stage diffuse large B cell lymphoma in elderly patients Lobna A. Abdelaziz 1, Reham A. Salem 1, Nabila Hefzi
More informationPET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma. Ranjana H. Advani, MD
PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma Ranjana H. Advani, MD Stanford Cancer Institute Management of Hodgkin Lymphoma Learning Objectives Review risk adapted strategies
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationTargeted Radioimmunotherapy for Lymphoma
Targeted Radioimmunotherapy for Lymphoma John Pagel, MD, PhD Fred Hutchinson Cancer Center Erik Mittra, MD, PhD Stanford Medical Center Brought to you by: Financial Disclosures Disclosures Erik Mittra,
More informationAggressive B and T cell lymphomas: Treatment paradigms in 2018
Aggressive B and T cell lymphomas: Treatment paradigms in 2018 John P. Leonard M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Associate
More informationThe case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation
More informationPost-ESMO Berne
Post-ESMO Berne 23.10.2015 Lymphoma Update Panagiotis Samaras Department of Oncology Hemato-Oncology Center University Hospital Zurich Diffuse Large B-Cell Lymphoma (DLBCL) PCNSL Hodgkin s Lymphoma Mantle
More informationPET-imaging: when can it be used to direct lymphoma treatment?
PET-imaging: when can it be used to direct lymphoma treatment? Luca Ceriani Nuclear Medicine and PET-CT centre Oncology Institute of Southern Switzerland Bellinzona Disclosure slide I declare no conflict
More informationTHE EORTC-GELA TREATMENT STRATEGY IN CLINICAL STAGES I-II HL Results of the H9-F and H9-U trials (#20982)
EORTC Lymphoma Group THE EORTC-GELA TREATMENT STRATEGY IN CLINICAL STAGES I-II HL Results of the H9-F and H9-U trials (#20982) J. Thomas, C. Fermé, E.M. Noordijk, H. Eghbali and M. Henry-Amar 7th International
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationModified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma
ORIGINAL ARTICLE DOI: 10.3904/kjim.2010.25.3.301 Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma Changhoon Yoo
More informationLymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient?
Lymphocyte Predominant Hodgkin s Lymphoma Wei Ai, MD, PhD Assistant Clinical Professor University of California, San Francisco January 2010 Case Presentation 32 yo male, diagnosed with stage IIIA lymphocyte
More informationAggressive lymphomas ASH Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV
Aggressive lymphomas ASH 2015 Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV CHOP 1992 2002 R-CHOP For DLBCL High dose chemo With PBSCT Aggressive lymphomas 1.DLBCL 2.Primary Mediastinal Lymphoma 3.CNS
More informationRadiation and Hodgkin s Disease: A Changing Field. Sravana Chennupati Radiation Oncology PGY-2
Radiation and Hodgkin s Disease: A Changing Field Sravana Chennupati Radiation Oncology PGY-2 History of Present Illness 19 yo previously healthy male college student began having pain in his R shoulder
More informationCAR-T cell therapy pros and cons
CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research
More informationDiffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma (DLBCL) DLBCL/MCL Dr. Anthea Peters, MD, FRCPC University of Alberta/Cross Cancer Institute Disclosures Honoraria from Janssen, Abbvie, Roche, Lundbeck, Seattle Genetics Objectives
More informationInterim PET in Diffuse Large B Cell Lymphoma.The GEL/TAMO experience
Interim PET in Diffuse Large B Cell Lymphoma.The GEL/TAMO experience MD. Caballero, Hospital Universitario, Salamanca, Spain. Chair of The GEL/TAMO Group Menton,9 april 2010 Disclosures for Dolores Caballero
More informationIAEA Pediatric Radiation Oncology Training Dr Laskar Version 1 June 2009 RADIATION THERAPY FOR PEDIATRIC HODGKIN S DISEASE
RADIATION THERAPY FOR PEDIATRIC HODGKIN S DISEASE THOMAS HODGKIN 1832 On Some Morbid Appearances of the Absorbent Glands & Spleen GLOBAL INCIDENCE Region Cases per 100,000 children United States 0.5 European
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationBLOOD RESEARCH ORIGINAL ARTICLE INTRODUCTION
BLOOD RESEARCH VOLUME 50 ㆍ NUMBER 3 September 2015 ORIGINAL ARTICLE Prediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous
More informationHighlights of ICML 2015
Highlights of ICML 2015 Jonathan W. Friedberg M.D. Director, James P. Wilmot Cancer Center Statistics, ICML 2015: a global meeting Almost 3700 participants. 90 countries represented. Attendees: USA 465
More informationMantle Cell Lymphoma New scenario and concepts in front-line treatment for young pa:ents
Mantle Cell Lymphoma New scenario and concepts in front-line treatment for young pa:ents Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Ke=ering Cancer Center Friday March 16, 2018: 11:15-11:30
More informationAdvanced stage HL The old and new match: BEACOPP
27.03.2015 1 Advanced stage HL The old and new match: BEACOPP Peter Borchmann German Hodgkin Study Group University of Cologne, Germany Which answer is wrong? For patients with advanced stage HL, treatment
More informationChristian Rübe, and Michael Pfreundschuh, J Clin Oncol 32: by American Society of Clinical Oncology INTRODUCTION
VOLUME 32 NUMBER 11 APRIL 1 14 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Role of Radiotherapy to Bulky Disease in Elderly Patients With Aggressive B-Cell Lymphoma Gerhard Held, Niels Murawski,
More informationAdjuvant Radiotherapy for completely resected NSCLC
Adjuvant Radiotherapy for completely resected NSCLC ESMO Preceptorship on lung Cancer Manchester February 2017 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique Local
More informationTreating for Cure or Palliation: Difficult Decisions for Older Adults with Lymphoma
Treating Frail Adults With Common Malignancies: Best Evidence to Personalize Therapy Treating for Cure or Palliation: Difficult Decisions for Older Adults with Lymphoma Raul Cordoba, MD, PhD Lymphoma Unit
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationSEQUENCING FOLLICULAR LYMPHOMA
SEQUENCING FOLLICULAR LYMPHOMA Thomas E. Witzig, MD October 24, 2015 Disclosures All presenters were independently selected by the organizing committee. Those presenters who disclosed affiliations or financial
More informationTreatment of Early Stage Hodgkin Lymphoma. Massimo Federico University of Modena and Reggio Emilia Città di Lecce Hospital - GVM Care & Research
Treatment of Early Stage Hodgkin Lymphoma Massimo Federico University of Modena and Reggio Emilia Città di Lecce Hospital - GVM Care & Research Conflict of Interest Disclosure I hereby declare the following
More informationRT in Hodgkin Lymphoma
RT in Hodgkin Lymphoma Lesser is better? Philip Poortmans, M.D. Ph.D. Radiation oncologist Tilburg, The Netherlands Radiation dose in Hodgkin Lymphoma Introduction Current evidence Guidelines 1.0 Early
More informationPolicy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies
Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies UNCONTROLLED WHEN PRINTED Note: NOSCAN Haematology MCN has approved the information contained within this document to guide
More informationMantle Cell Lymphoma: Update in Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency
Mantle Cell Lymphoma: Update in 2015 Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency Disclosures Research funding: Roche provides research funding to support the Centre for Lymphoid Cancer
More informationDiffuse Large B-Cell Lymphoma Front line Therapy John P. Leonard, MD Weill Cornell Medicine New York, New York USA
Diffuse Large B-Cell Lymphoma Front line Therapy John P. Leonard, MD Weill Cornell Medicine New York, New York USA Disclosures Consulting advice: Hospira, Bayer, Juno Therapeutics, Teva, Oncotracker, Gilead
More informationDisclosures for Dr. Peter Borchmann 48 th ASH Annual meeting, Orlando, Florida
Phase II Study of Pixantrone in Combination with Cyclophosphamide, Vincristine, and Prednisone (CPOP) in Patients with Relapsed Aggressive Non-Hodgkin s Lymphoma P Borchmann Universitaet de Koeln, Koeln,
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationROB LOWN SOUTHAMPTON HODGKIN LYMPHOMA IN THE ELDERLY
ROB LOWN SOUTHAMPTON HODGKIN LYMPHOMA IN THE ELDERLY EPIDEMIOLOGY HODGKIN LYMPHOMA - INCIDENCE EPIDEMIOLOGY HODGKIN LYMPHOMA - MORTALITY EPIDEMIOLOGY HODGKIN LYMPHOMA - MORTALITY BY AGE NUMBER OF PEOPLE
More informationR/R DLBCL Treatment Landscape
An Updated Analysis of JULIET, a Global Pivotal Phase 2 Trial of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Abstract S799 Borchmann P, Tam CS, Jäger U,
More informationCure, Late Effects and Prevention in Hodgkin Lymphoma
Cure, Late Effects and Prevention in Hodgkin Lymphoma Michael Crump, MD, FRCPC Princess Margaret Hospital University of Toronto Toronto, Canada Objectives/Outline review progress in treatment of HL outline
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationWorkshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI
XXI CONGRESSO NAZIONALE AIRO Genova, 19-22 novembre 2011 Workshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI PIERA NAVARRIA Unità Operativa di Radioterapia e Radiochirurgia Humanitas Cancer
More informationOverview. Table of Contents. A Canadian perspective provided by Isabelle Bence-Bruckler, MD, FRCPC
2 A C A N A D I A N P E R S P E C T I V E Volume 2 November 2005 Overview The International Conference on Malignant Lymphoma (ICML) is held every three years in Lugano, Switzerland. ICML started nearly
More informationLYMPHOMA in HIV PATIENTS. Silvia Montoto, St Bartholomew s Hospital, London, UK ESMO Preceptorship on Lymphoma
LYMPHOMA in HIV PATIENTS Silvia Montoto, St Bartholomew s Hospital, London, UK ESMO Preceptorship on Lymphoma Lugano, 3-4 November 2017 Disclosures: Roche: honoraria Gilead: travel grant ESMO Preceptorship
More informationB Cell Lymphoma: Aggressive
B Cell Lymphoma: Aggressive UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: Ibrutinib approved for mantle cell lymphoma as 2nd line therapy. - Aggressive lymphomas are a group of malignant
More informationToday, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center
Today, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center Today, how many PTCL patients are cured? Some but not as many
More informationManagement of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT
Management of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan Kettering Cancer Center Disclosure Consulting
More informationRituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's Lymphoma
Page 1 of 5 Home Search Study Topics Glossary Search Full Text View Tabular View No Study Results Posted Related Studies Rituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's
More informationPrognostic Value of Early Introduction of Second Line in Patients with Diffuse Large B Cell Lymphoma
Med. J. Cairo Univ., Vol. 84, No., December: 443-447, 6 www.medicaljournalofcairouniversity.net Prognostic Value of Early Introduction of Second Line in Patients with Diffuse Large B Cell Lymphoma HAMDY
More informationLymphomas in Prof Paul Ruff Division of Medical Oncology
Lymphomas in 2010 Prof Paul Ruff Division of Medical Oncology Most Common Lymphomas: ~90% B-cell and ~10% T-cell T lymphoblastic: 2% Marginal zone, nodal: 2% Other: 9% Burkitt: 2% Anaplastic large cell:
More informationJOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
VOLUME 24 NUMBER 19 JULY 1 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
More informationWho should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University
Who should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University Treatment Challenges Several effective options, improve response durations, none curable
More informationAggressive NHL and Hodgkin Lymphoma. Dr. Carolyn Faught November 10, 2017
Aggressive NHL and Hodgkin Lymphoma Dr. Carolyn Faught November 10, 2017 What does aggressive mean? Shorter duration of symptoms Generally need treatment at time of diagnosis Immediate, few days, few weeks
More informationGerman Hodgkin Study Group
German Hodgkin Study Group Deutsche Hodgkin Studiengruppe Avoiding Relapse of Hodgkin Lymphoma: Have We Moved The Needle? Andreas Engert, MD Chairman, German Hodgkin Study Group University Hospital of
More informationeastern cooperative oncology group Michael Williams, Fangxin Hong, Brad Kahl, Randy Gascoyne, Lynne Wagner, John Krauss, Sandra Horning
Results of E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Indolent B-Cell Lymphoma Michael Williams, Fangxin Hong, Brad Kahl, Randy
More informationPET-CT in Peripheral T-cell Lymphoma: To Be or Not To Be
PET-CT in Peripheral T-cell Lymphoma: To Be or Not To Be Bruce D. Cheson, M.D. Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington, DC, USA So What is the Question(s)? What is
More informationUpdates in the Treatment of Non-Hodgkin Lymphoma: ASH Topics
Updates in the Treatment of Non-Hodgkin Lymphoma: ASH 2008 Joseph Tuscano, M.D. UC Davis Cancer Center 1 Topics Mantle Cell Lymphoma What is the standard of care for younger patients? (abstracts 581, 769,
More informationTransformed lymphoma: biology and treatment
Transformed lymphoma: biology and treatment Silvia Montoto Centre for Haemato-Oncology Barts Cancer Institute 1.00 0.75 0.50 0.25 0.00 N =330 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 Years %Viability
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationComparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL):
Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial H. Eghbali, P.
More informationESMO Preceptorship Programme, Colorectal Cancer, Vienna
State of the art multimodal treatment of anal cancer ESMO Preceptorship Programme, Colorectal Cancer, Vienna Rob Glynne-Jones Mount Vernon Centre for Cancer Treatment Disclosures: last 5 years Speaker:
More information